FDA: Certain COVID-19 tests must evaluate how variants affect performance
The Food and Drug Administration today certain COVID-19 test developers to evaluate how SARS-CoV-2 mutations impact their test鈥檚 performance and update the labeling for the product accordingly. The new conditions for emergency use authorization pertain to certain authorized molecular, antigen and .
Related News Articles
Headline
The Food and Drug Administration today issued an alert on a potentially high-risk issue with Calyxo CVAC Aspiration Systems. In patients who have thick fluid鈥�
Headline
In this conversation, Carlos Roberts, M.D., urogynecologist, vice president and chief medical officer of the Women and Children service line at WellSpan Health鈥�
Headline
In this 鈥淪afety Speaks鈥� conversation, CommonSpirit Health's Beth Miller, system director, patient safety-performance improvement, and Austin Peterson, system鈥�
Headline
CDC recommends two doses of COVID-19 vaccine for older individuals, lowers pneumococcal vaccine age聽
The Centers for Disease Control and Prevention last week endorsed a recommendation for people aged 65 and older and for immunocompromised individuals to鈥�
Headline
The Centers for Medicare & Medicaid Services Oct. 22 released final guidance detailing reporting requirements for the hospital respiratory data condition鈥�
Headline
The Food and Drug Administration Aug. 22 granted emergency use authorization for two new combined COVID-19 and influenza tests. The Nano-Check Influenza-COVID-鈥�